Compare Goldman Sachs Physical Gold ETF (AAAU) vs Abeona Therapeutics Inc (ABEO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Goldman Sachs Physical Gold ETF vs Abeona Therapeutics Inc — how do they compare? Goldman Sachs Physical Gold ETF trades at $43.54, while Abeona Therapeutics Inc trades at $7.38 (market cap $421.19M). The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, Goldman Sachs Physical Gold ETF nearer its low. Which is the better fit depends on your goals.
| AAAU | ABEO | |
|---|---|---|
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $53.21 | $7.45 |
52-Week Low | $32.74 | $4.17 |
Market Cap | — | $421.19M |
Enterprise Value | — | $276.10M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AAAU, a US-listed gold-focused stock, trades at $43.73, up 1.06% with a bullish technical signal from moving averages but bearish oscillators. Recent news highlights gold's strength amid cooling US inflation and geopolitical tensions, with spot gold reaching $4,438/oz (Kitco, 2026-08-12). Financial ratios are unavailable, limiting fundamental clarity.
The outlook is mixed: technical momentum supports near-term gains, but overbought RSI levels suggest caution. Gold's appeal as a safe-haven asset amid economic uncertainty offers upside, yet reliance on commodity prices and absent financial metrics pose risks for stock investors.
ABEO trades at $7.365, down 1.14% today, amid a bullish technical outlook with moving averages signaling strength. The company reported a net income of $71.18 million in 2025, with a net margin of 454.86%, though revenue remains modest at $5.82 million. Recent news includes CMS granting NTAP status for ZEVASKYN and expanding its treatment center network, indicating commercial progress.
The outlook is supported by strong analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high SG&A expenses relative to revenue and a shareholder investigation. Upside hinges on revenue scaling to justify current valuations, with the Q2 2026 earnings call on August 13, 2026, as a key near-term catalyst.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Goldman Sachs Physical Gold ETF
AAAU tracks the price of gold bullion by holding physical gold bars in secure vaults. Managed by Goldman Sachs, this ETF offers a cost-effective way to gain direct exposure to gold without the logistical challenges of storage or insurance.
Read more on AAAU →About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →
